UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib

Cardiovascular toxicology, 2017-07, Vol.17 (3), p.237-250

2017

Volltextzugriff (PDF)

Mechanisms of Myocyte Cytotoxicity Induced by the Multiple Receptor Tyrosine Kinase Inhibitor Sunitinib

Molecular pharmacology, 2008-12, Vol.74 (6), p.1722-1728

2008

Volltextzugriff (PDF)

Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs

Molecules (Basel, Switzerland), 2018-08, Vol.23 (8), p.2041

2018

Volltextzugriff (PDF)

The use of dexrazoxane for the prevention of anthracycline extravasation injury

Expert opinion on investigational drugs, 2008-02, Vol.17 (2), p.217-223

Hasinoff, Brian B

2008

Volltextzugriff (PDF)

The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity

Toxicology and applied pharmacology, 2010-04, Vol.244 (2), p.190-195

Hasinoff, Brian B.

2010

Volltextzugriff (PDF)

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy

Toxicology (Amsterdam), 2009-01, Vol.255 (1), p.72-79

2009

Volltextzugriff (PDF)

The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro

Toxicology and applied pharmacology, 2010-12, Vol.249 (2), p.132-139

2010

Volltextzugriff (PDF)

Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity

Archives of biochemistry and biophysics, 2017-11, Vol.633, p.23-28

2017

Volltextzugriff (PDF)

Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor Sorafenib

Cardiovascular toxicology, 2010-03, Vol.10 (1), p.1-8

2010

Volltextzugriff (PDF)

Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform

The Journal of pharmacology and experimental therapeutics, 2016-02, Vol.356 (2), p.397

2016

Volltextzugriff (PDF)

Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib

Cardiovascular toxicology, 2020-08, Vol.20 (4), p.380-389

2020

Volltextzugriff (PDF)

A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II

Bioorganic & medicinal chemistry, 2010-01, Vol.18 (2), p.830-838

2010

Volltextzugriff (PDF)

The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II)

Journal of inorganic biochemistry, 2014-08, Vol.137, p.22-30

2014

Volltextzugriff (PDF)

The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity

Cardiovascular toxicology, 2017-07, Vol.17 (3), p.297-306

2017

Volltextzugriff (PDF)

Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu(II), Ni(II) and Pt(II)

Journal of inorganic biochemistry, 2013-09, Vol.126, p.1-6

2013

Volltextzugriff (PDF)

Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F

Free radical biology & medicine, 2007-10, Vol.43 (8), p.1132-1144

2007

Volltextzugriff (PDF)

Total Synthesis of Isoprekinamycin: Structural Evidence for Enhanced Diazonium Ion Character and Growth Inhibitory Activity toward Cancer Cells

Organic letters, 2007-07, Vol.9 (15), p.2915-2918

2007

Volltextzugriff (PDF)

Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II)

Biochemical pharmacology, 2015-02, Vol.93 (3), p.266-276

2015

Volltextzugriff (PDF)

The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites

Drug metabolism and disposition, 2008-09, Vol.36 (9), p.1780-1785

2008

Volltextzugriff (PDF)

Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat

Drug metabolism and disposition, 2005-09, Vol.33 (9), p.1367-1372

2005

Volltextzugriff (PDF)

The Metabolites of the Cardioprotective Drug Dexrazoxane Do Not Protect Myocytes from Doxorubicin-Induced Cytotoxicity

Molecular pharmacology, 2003-09, Vol.64 (3), p.670-678

2003

Volltextzugriff (PDF)

The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II

Biochemical pharmacology, 2012-12, Vol.84 (12), p.1617-1626

2012

Volltextzugriff (PDF)

Dexrazoxane use in the prevention of anthracycline extravasation injury

Future oncology (London, England), 2006-02, Vol.2 (1), p.15-20

Hasinoff, Brian B

2006

Volltextzugriff (PDF)

The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα

Biochemical pharmacology, 2012-07, Vol.84 (1), p.52-58

2012

Volltextzugriff (PDF)

Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin–N-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNA

Bioorganic & medicinal chemistry, 2014-11, Vol.22 (21), p.5935-5949

2014

Volltextzugriff (PDF)

1 – 25 von 125

Suche als RSS-Feed

Aktive Filter

KollektionCambridge Journals Online (DEFF)

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(123)
Mit Volltextzugriff
(111)

Publikationsform

Artikel
(125)

Sprache

Englisch
(125)

Erscheinungsjahr

n.n

Thema

Science & Technology
(114)
Life Sciences & Biomedicine
(113)
Animals
(70)
Pharmacology & Pharmacy
(57)
Biological And Medical Sciences
(49)
Biochemistry & Molecular Biology
(47)
Humans
(47)
Medical Sciences
(41)
Rats
(35)
Pharmacology. Drug Treatments
(32)
Chemistry
(31)
Physical Sciences
(30)
Kinetics
(29)
Doxorubicin
(28)
Rats, Sprague-Dawley
(28)
Razoxane - Pharmacology
(27)
Antineoplastic Agents - Pharmacology
(26)
K562 Cells
(26)
Topoisomerase Ii Inhibitors
(24)
Dexrazoxane
(23)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib

Mechanisms of Myocyte Cytotoxicity Induced by the Multiple Receptor Tyrosine Kinase Inhibitor Sunitinib

Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs

The use of dexrazoxane for the prevention of anthracycline extravasation injury

The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy

The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro

Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity

Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor Sorafenib

Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform

Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib

A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II

The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II)

The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity

Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu(II), Ni(II) and Pt(II)

Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F

Total Synthesis of Isoprekinamycin: Structural Evidence for Enhanced Diazonium Ion Character and Growth Inhibitory Activity toward Cancer Cells

Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II)

The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites

Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat

The Metabolites of the Cardioprotective Drug Dexrazoxane Do Not Protect Myocytes from Doxorubicin-Induced Cytotoxicity

The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II

Dexrazoxane use in the prevention of anthracycline extravasation injury

The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα

Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin–N-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNA

Aktive Filter

Suchergebnisse filtern